Skip to main content

Peer Review reports

From: RUNX1 is a promising prognostic biomarker and related to immune infiltrates of cancer-associated fibroblasts in human cancers

Original Submission
20 Jan 2022 Submitted Original manuscript
10 Feb 2022 Reviewed Reviewer Report - Atsushi Takano
3 Mar 2022 Reviewed Reviewer Report
27 Mar 2022 Author responded Author comments - Liangkuan Bi
Resubmission - Version 2
27 Mar 2022 Submitted Manuscript version 2
30 Mar 2022 Author responded Author comments - Liangkuan Bi
Resubmission - Version 3
30 Mar 2022 Submitted Manuscript version 3
31 Mar 2022 Author responded Author comments - Liangkuan Bi
Resubmission - Version 4
31 Mar 2022 Submitted Manuscript version 4
6 Apr 2022 Reviewed Reviewer Report - Atsushi Takano
21 Apr 2022 Reviewed Reviewer Report
26 Apr 2022 Author responded Author comments - Liangkuan Bi
Resubmission - Version 5
26 Apr 2022 Submitted Manuscript version 5
Publishing
3 May 2022 Editorially accepted
9 May 2022 Article published 10.1186/s12885-022-09632-y

You can find further information about peer review here.

Back to article page